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Baculovirus holds great promise for the genetic modi-
fication of mesenchymal stem cells (MSCs). However, 
whether baculovirus transduction provokes undesired 
MSCs responses that might compromise their in vivo 
applications has yet to be examined. Hereby, we unrav-
eled that baculovirus transduction of human MSCs upreg-
ulated the transcription of interleukin (IL)-1β, interferon 
(IFN)-α and IL-6, but not tumor necrosis factor (TNF)-α 
and IFN-γ. However, only IL-6 secretion was detectable 
by enzyme-linked immunosorbent assay (ELISA). Bacu-
lovirus transduction also stimulated transient, low level 
upregulation of human leukocyte antigen I (HLA-I) on 
the human MSCs surface, yet it did not either altered the 
HLA-II expression or impaired the MSCs ability to inhibit 
lymphocyte proliferation. After transplantation into allo-
geneic rats, the transduced rat MSCs  elicited transient, 
mild macrophage responses, but the cells remained 
 tolerant as judged by the persistence of transplanted 
cells and absence of CD8+ T cells infiltration. Besides, 
transplantation of the transduced MSCs did not provoke 
systemic induction of monocytes and CD8+ T cells. This 
study, for the first time, explores the responses of MSCs to 
virus transduction and confirms the safety of transplant-
ing baculovirus-engineered MSCs into immunocompe-
tent animals for cell-based gene therapy.
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10 March 2009. doi:10.1038/mt.2009.30
IntroductIon
Bone marrow mesenchymal stem cells (MSCs) are capable of 
self-renewal and multilineage differentiation into various cell 
types including adipocytes, chondrocytes and osteoblasts1,2 under 
appropriate environmental cues. Additionally, MSCs are immu-
noprivileged and can suppress lymphocyte alloreactivity in mixed 
lymphocyte cultures.3 These characteristics have captured inter-
ests to exploit MSCs as a promising cell therapy source. Moreover, 
MSCs can be engineered by gene delivery vectors and serve as a 
platform for cell-based gene therapy.1 By genetic modification, 
MSCs can express therapeutic proteins that promote or modulate 
the MSCs differentiation and accelerate tissue/organ regenera-
tion in vivo. However, the gene delivery vectors in common use 
 possess various drawbacks of their own (for review see ref. 4). For 
example, retrovirus and lentivirus are prone to integration into 
coding or regulatory regions of transcriptionally active genes,5 
raising concerns about gene silencing and insertional  mutagenesis. 
Adenovirus mounts strong immune responses, which may com-
promise its therapeutic effects in vivo. Adeno-associated virus 
is successfully employed for MSCs engineering, yet its cloning 
capacity is limited. Moreover, hepatocellular carcinoma  resulting 
from adeno-associated virus-mediated gene therapy has been 
reported,6 thus calling the safety of adeno-associated virus vector 
into question.
Aside from these vectors, baculovirus (Autographa  californica 
multiple nucleopolyhedrovirus) has emerged as a novel gene 
delivery vector in recent years. As a DNA virus that infects insect 
as its natural host, baculovirus does not either replicate or is not 
toxic inside the transduced cells (for review, see refs. 7–10) and 
baculoviral DNA degrades in the mammalian cells over time,11,12 
thus easing the safety concerns about the use of  baculovirus for 
gene therapy. Moreover, baculovirus can transduce human bone 
marrow–derived MSCs at efficiencies >95% under  optimized 
conditions,13 and the transduced MSCs remain  capable of dif-
ferentiation into adipogenic, osteogenic, and chondrogenic 
lineages.11,14 Transduction of human MSCs ex vivo with a recom-
binant baculovirus that expresses the osteoinductive bone 
 morphogenetic protein-2 triggers in vitro differentiation of MSCs 
into osteoblasts, and transplantation of the transduced cells into 
the back subcutis of immunodeficient nude mice results in ecto-
pic bone formation.15 These data collectively implicate the poten-
tial of baculovirus for ex vivo–genetic modification of MSCs and 
 bone-tissue engineering.
Although baculovirus holds great promise for MSCs engi-
neering, it has been uncovered that baculovirus transduction of 
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differentiated mammalian cells [e.g., hepatocytes, macrophages, 
and dendritic cells (DCs)] triggers antiviral effects and innate 
immunity, as evidenced by the upregulation of a panel of  cytokines 
including interleukin (IL)-6 and interferons (IFNs) (e.g., IFN-α 
and IFN-β).16–20 Moreover, in vivo administration of baculovirus 
provokes cell-mediated immune responses including the activa-
tion of DCs, natural killer cells, and antigen-specific CD4+ and 
CD8+ T cells.21–23 These findings raise the question regarding 
whether baculovirus transduction of the undifferentiated MSCs 
provokes the same responses, and how the responses may  influence 
the applications of baculovirus in the context of MSCs-based gene 
therapy. To address these questions, in this study, we investigated 
whether baculovirus transduction triggered cytokine responses 
and altered the immunological properties of MSCs. Whether 
transplantation of the baculovirus-transduced MSCs into immu-
nocompetent animals elicited undesired rejection responses was 
also investigated.
results
cytokine expression by baculovirus-transduced Mscs
Since we have demonstrated the potential of human MSCs in 
 tissue engineering, we first sought to determine whether human 
MSCs express inflammatory cytokines in response to baculo-
virus transduction. To avoid the responses elicited by the trans-
gene, human MSCs were transduced with a baculovirus that 
expressed no transgene. As controls, the cells were either mock-
transduced or incubated with the virus-free culture supernatant 
 (supernatant). The gene transcription levels were measured by 
quantitative  real-time reverse transcription PCR at different times 
and normalized against that of the mock-transduction control at 
12 hours post-transduction (hpt).
When compared with the mock-transduction control, incu-
bation of MSCs with the insect cell culture supernatant did not 
 provoke the upregulation of IL-1β, IFN-α and IL-6 at all time points 
(Figure 1a–c), but baculovirus transduction led to approximately 
two- to fourfold increases (P < 0.05) in the IL-1β and IFN-α tran-
scription from 12 to 144 hpt (Figure 1a,b). Baculovirus transduc-
tion also gave rise to ≈12-fold upregulation of IL-6 at 24 hpt, which 
gradually waned thereafter (Figure 1c). However, neither baculo-
virus nor the supernatant significantly elicited the tumor necrosis 
factor (TNF)-α and IFN-γ transcription (data not shown).
In line with the transcription data, the enzyme-linked immu-
nosorbent assay (ELISA) data revealed that  baculovirus trans-
duction of MSCs provoked IL-6 secretion (Figure 2), which 
culminated at 24 hpt (≈676.5 pg/105 cells/24 hours) and then 
decreased precipitously thereafter (Figure 2). However, the 
supernatant did not trigger IL-6 secretion at levels significantly 
higher than that of mock-transduction controls. In contrast, the 
 secretion of IL-1β and IFN-α by baculovirus-transduced MSCs 
fell below the detection limits of ELISA kits (<3.9 pg/ml for IL-1β 
and <8 pg/ml for IFN-α, data not shown), probably because the 
upregulation of these genes was not pronounced enough.
Human leukocyte antigen expression on the 
baculovirus-transduced Mscs
Human MSCs are immunoprivileged at least partly because they 
express moderate levels of class I human leukocyte antigen (HLA-I) 
and low levels of HLA-II,24 which play pivotal roles in determining 
the compatibility after tissue transplantation. To examine whether 
baculovirus transduction altered the immunological characteris-
tics, we quantified the surface HLA by immunofluorescence label-
ing and flow cytometry. Prior to transduction, MSCs expressed 
moderate levels of HLA-I (percentage of fluorescing cells ≈91%, 
mean fluorescence intensity (MFI) ≈442) and low levels of HLA-II 
(percentage of fluorescing cells ≈0.2%, MFI ≈29, data not shown). 
Compared with the HLA-I expression on the mock-transduction 
controls (pink lines), the HLA-I expression levels on the surface of 
baculovirus-transduced cells (green lines) were elevated at 24 hpt 
(Figure 3a) and 48 hpt (Figure 3b), as evidenced by the significantly 
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Figure 1 cytokine expression by baculovirus-transduced Mscs. 
(a) IL-1β; (b) IFN-α; (c) IL-6. Human MSCs were transduced by a bacu-
lovirus that expressed no transgene at multiplication of infection 100. As 
controls, MSCs were mock-transduced (Mock) or treated with virus-free 
insect cell culture supernatant (Supernatant). The transcription levels of 
IL-1β, IFN-α, IL-6, TNF-α, and IFN-γ were measured by quantitative real-
time reverse transcription-PCR at different times and normalized against 
that of the mock-transduction control at 12 hpt. The IFN-γ and TNF-α 
transcription levels were not significantly higher than the baseline levels 
and are not shown. IFN, interferon; IL, interleukin; MSCs, mesenchymal 
stem cells; TNF, tumor necrosis factor.
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Figure 2 secretion of inflammatory cytokine (Il-6) by baculovirus-
transduced Mscs. The MSCs were transduced as in Figure 1. After 
transduction, the spent media from the MSCs culture were  completely 
replaced with fresh media at 24, 48, and 96 hpt. The  concentrations of 
IL-1β, IFN-α, and IL-6 in the spent media were measured by ELISA. The 
IL-1β and IFN-α concentrations are not shown because they are lower than 
the detection limits of ELISA kits. ELISA, enzyme-linked  immunosorbent 
assay; IFN, interferon; IL, interleukin; MSCs,  mesenchymal stem cells.
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(P < 0.01) elevated MFI (from ≈430 to ≈1,003 at 24 hpt and from 
≈417 to ≈1,262 at 48 hpt). Nonetheless, at 144 hpt (Figure 3c) the 
HLA-I expression  considerably decreased as the MFI dropped 
(≈439) and approached that of the  mock- transduction control. 
In contrast to HLA-I, the surface levels of HLA-II remained simi-
larly low for the transduced and mock-transduced cells at all time 
points, indicating negligible induction of HLA-II by baculovirus 
transduction.
Baculovirus-transduced Mscs remained capable  
of inhibiting lymphocyte proliferation
Human MSCs suppress lymphocyte proliferation in vitro in 
mixed lymphocyte cultures.3,25 This immunosuppressive  property 
is essential for MSCs, allowing them to repress the severe 
graft-versus-host disease after transplantation into patients.26 
To investigate whether baculovirus-transduced MSCs still 
retained the immunosuppressive property, the transduced and 
 mock-transduced MSCs were harvested at different times (24, 48, 
or 144 hpt) for coculture with peripheral blood mononuclear cells 
(PBMC). The PBMC were stimulated with phytohaemaggluti-
nin-L and their proliferation was measured 3 days after coculture 
by a  bromodeoxyuridine (BrdU) proliferation kit.27 In comparison 
with the PBMC that were  cultured alone (Figure 4), the PBMC 
proliferation was significantly inhibited (P < 0.05) when cocul-
tured with either the mock-transduced or transduced MSCs. The 
levels of inhibition were statistically similar between the transduc-
tion and mock-transduction groups (P > 0.05), regardless of when 
(24, 48, or 144 hours) the MSCs were  collected for coculture.
distribution and survival of the transplanted Mscs
MSCs can escape immune recognition and suppress T cells acti-
vation in vivo.28 To explore whether baculovirus transduction of 
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Figure 3 surface expression of HlA-I and HlA-II on the baculovirus-transduced Mscs. The transduced MSCs were detached at (a) 24, 
(b) 48, and (c) 144 hpt for immunofluorescence labeling and flow cytometry analysis (green lines). The mock-transduced cells were treated  similarly 
as the control (pink lines). HLA, human leukocyte antigen; MFI, mean fluorescence intensity; MSCs, mesenchymal stem cells; POF, percentage of 
fluorescing cells.
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MSCs resulted in the loss of the immunomodulatory properties 
in vivo, we have transplanted human MSCs into the quadriceps 
of LEW/SsNNarl rats. However, these xenogeneic cells were seri-
ously rejected as evidenced by rapid cell clearance and acute infil-
tration of macrophages and CD8+ T cells (data not shown). To 
circumvent the xenorejection, allogeneic bone marrow– derived 
MSCs were isolated from LEW/SsNNarl rats, transduced as 
described above, prelabeled with BrdU, trypsinized at 24 hpt, and 
then co-injected with carbon black (to track the location of the 
transplanted cells) into the quadriceps of LEW/SsNNarl rats. For 
comparison, the mock-transduced rat MSCs were treated and 
injected in a similar fashion.
The tissue specimens colocalizing with the carbon black were 
removed at different time post-transplantation and examined by 
Hematoxylin and Eosin staining (Figure 5a) and immunohis-
tochemical staining specific for BrdU (Figure 5b). Figure 5a shows 
that the injected cells were distributed near the muscle  tissues and 
there was no apparent sign of immune cell  infiltration. Similarly, 
Figure 5b reveals that the transduced and mock- transduced 
MSCs (orange cells) persisted near the muscle tissues and a large 
portion of the cells survived at 10 days post- transplantation. There 
appeared to be no manifest decrease in the number of transplanted 
MSCs over time, and there was no difference in the number of 
transplanted cells between the mock-transduction and the trans-
duction groups.
In vivo immune responses
To assess the local immune responses triggered by the baculo-
virus-transduced MSCs, the infiltration of cells representative 
of the innate immunity (macrophages) and adaptive immunity 
(CD8+ T cells) was detected by immunohistochemical s taining. 
CD4+ T cells were not examined as their activation requires HLA-
II-mediated peptide presentation, which was minimal in MSCs 
(Figure 3). Figure 6a illustrates scarce distribution of macrophages 
(cells that stained green on the membrane) at the injection site of 
the mock-transduction group at day 1, and no signs of increased 
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Figure 4 Baculovirus (Bac)-transduced Mscs remained capable 
of inhibiting lymphocyte proliferation. MSCs were transduced or 
mock-transduced as in Figure 1 and the cells were harvested 24, 48, 
or 144 hours later for mixed lymphocyte culture. The PBMC (2 × 105 cells/
well) were stimulated with phytohaemagglutanin-L and cocultured with 
the MSCs (2 × 104 cells/well) in the 96-well plates. The PBMC prolifera-
tion was measured 3 days after coculture by a bromodeoxyuridine pro-
liferation kit. MSCs, mesenchymal stem cells; PBMC, peripheral blood 
mononuclear cells.
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Figure 5 distribution and survival of the transplanted Mscs. 
(a) Hematoxylin and Eosin staining. (b) Immunohistochemical staining. 
The transduced and mock-transduced rat MSCs were prelabeled with 
bromodeoxyuridine (BrdU) and co-injected with carbon black into the 
quadriceps of LEW/SsNNarl rats. The location of the transplanted cells 
was identified with the aid of the carbon black, and the tissue specimens 
were removed at 1, 5, or 10 days post-transplantation. The prelabeled 
MSCs were probed with the anti-BrdU monoclonal antibody and visual-
ized with the Alexa 488-conjugated secondary antibody (green), while 
all nucleated cells were stained by 4ʹ,6-diamidino-2-phenylindole (red), 
therefore the transplanted cells appear orange after superimposing the 
images. n = 3 for each time point. The original magnifications were ×200 
(scale bars =100 µm). The enlarged images (magnification, ×1,000) are 
shown in the insets. MSCs, mesenchymal stem cells.
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Figure 6 Infiltration of macrophages and cd8+ t cells into the trans-
plantation site. (a) Immunohistochemical staining for macrophages. 
(b) Immunohistochemical staining for CD8+ T cells. The immune cells 
were visualized with Alexa 488-conjugated secondary antibody and 
appeared green on the cell membrane. All nucleated cells were stained 
by 4ʹ,6-diamidino-2-phenylindole and appeared red. n = 3 for each time 
point. The original magnifications were ×200 (scale bars =100 µm). The 
enlarged images (magnification, ×1,000) are shown in the insets.
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 macrophage infiltration were observed through day 10. Conversely, 
at day 1, markedly more macrophages infiltrated into the injection 
site of the transduction group. The macrophage response subsided 
with time and nearly vanished at day 10. In contrast to the mac-
rophage response, very few CD8+ T cells (cells that stained green 
on the membrane) were detected in both the mock-transduction 
and transduction groups (Figure 6b) from day 1 to day 10. These 
data indicated that transplantation of  baculovirus-transduced 
MSCs only triggered local transient innate immune responses but 
not the adaptive immune responses.
To quantify the systemic immune responses, the animals 
transplanted with the transduced or mock-transduced MSCs 
were sacrificed at 1, 5, and 10 days post-transplantation and the 
PBMC were collected. In parallel, the PBMC were collected from 
healthy animals without transplantation to serve as the control. 
The  percentages of monocytes and CD8+ T cells in the PBMC 
 population were measured by flow cytometry analysis after immu-
nofluorescence labeling. Figure 7a shows slightly higher percent-
ages of monocytes in the baculovirus-transduction group than 
in the mock-transduction group at days 1, 5, and 10. However, 
the differences were not statistically significant at all time points 
(P > 0.05). Likewise, the percentage of CD8+ T cells was unchanged 
in the baculovirus-transduction group at all times as compared 
with the mock-transduction group (Figure 7b).
dIscussIon
Baculovirus is a promising tool for gene delivery into MSCs, 
thankfully due to its high transduction efficiency (>95%), and 
the recombinant baculovirus expressing bone morphogenetic 
protein-2 has been harnessed to accelerate the osteogenic dif-
ferentiation of MSCs and promote ectopic bone formation in 
immunodeficient animals.15 Given the numerous applications 
of genetically engineered MSCs1,2 (e.g., repair of cartilages and 
bones; repair of infracted myocardium; cancer therapy), baculovi-
rus-engineered MSCs potentially have a wide array of applications 
worth of exploration. However, whether baculovirus transduction 
evokes unwanted cellular responses that might compromise the 
use of MSCs in immunocompetent animals has yet to be exam-
ined. It has been uncovered that the toll-like receptors of MSCs 
can be stimulated by pathogen-associated molecular patterns 
(e.g., lipopolysaccharide and Pam3Cys), leading to the induction 
of various cytokines and alteration of the MSCs migration and 
immunomodulatory responses.29,30 Furthermore, MSCs may influ-
ence such effector cells as T cells, B cells and DCs via the release 
of cytokines.31 As such, gaining insight into how MSCs respond to 
baculovirus transduction (e.g., by secretion of cytokines) is crucial 
to the safe use of baculovirus-transduced MSCs in vivo.
By this means, we unraveled that baculovirus transduction 
of MSCs upregulated the expression of pro-inflammatory genes 
including IL-1β and IFN-α, but not TNF-α and IFN-γ (Figure 1). 
Nonetheless, the secretion levels of IL-1β and IFN-α were too 
low to be detected by ELISA. This expression profile contradicted 
the profiles in other differentiated, specialized cell types such as 
macrophages and DCs, which secrete IFNs (IFN-α, IFN-β, and 
IFN-γ) and TNF-α in response to baculovirus transduction,16–18 
and the disparity likely reflected the differences in the primitive-
ness of these cell types. IL-1β is a major mediator of  inflammation 
and can stimulate the MSCs to secrete IL-6.32 IFN-α, IFN-γ, and 
TNF-α are important immunomodulatory cytokines that can 
activate T cells and recruit other immune cells to potentiate the 
immune responses. Also, MSCs acquire antigen-presenting func-
tions following IFN-γ stimulation.28 As such, the absence of these 
cytokine responses reduces the possibility of mounting strong 
immune responses after transplantation.
In contrast to the aforementioned cytokines, IL-6 expres-
sion was markedly induced by baculovirus transduction as con-
firmed by quantitative real-time reverse transcription PCR and 
ELISA (Figures 1c and 2). It is known that IL-6 expression can be 
provoked as a result of virus infection and induction of toll-like 
receptor 3. In agreement with this notion, we found that baculo-
virus transduction stimulated the expression of toll-like  receptor 3 
(see Supplementary Figure S1), suggesting that baculovirus 
transduction may activate toll-like receptor 3. However, more 
experiments are required to confirm this finding. IL-6 is a com-
mon pro-inflammatory cytokine expressed by immune cells, and 
its overproduction is associated with the pathology of autoimmune 
diseases such as rheumatoid arthritis.29 Meanwhile, by nature, IL-6 
is expressed abundantly by MSCs derived from bone marrow and 
cord blood32,33 and its expression is implicated in the regulation of 
development, differentiation, proliferation, and migration of dif-
ferent stem cells.34 For instance, continuous exposure of MSCs to 
IL-6 for 3 weeks impedes MSC differentiation.29 These findings 
suggest that IL-6 induction may impact on MSCs differentiation 
and potentiate the inflammatory response after transplantation. 
Fortunately, baculovirus transduction only elicited transient pro-
duction of IL-6, which culminated at 24 hpt but subsided after 
48 hpt. The transient response explains why baculovirus transduc-
tion does not impair MSCs proliferation11 and differentiation14 
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Figure 7 Quantification of monocytes and cd8+ t cells in the PBMc 
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the PBMC population were measured by immunofluorescence  labeling/
flow cytometry. The PBMC collected from healthy animals without trans-
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ysis was performed by analysis of variance in conjunction with post hoc 
tests. PBMC, peripheral blood mononuclear cells.
894 www.moleculartherapy.org  vol. 17 no. 5 may 2009 
© The American Society of Gene Therapy
MSCs Responses to Baculovirus Transduction
in vitro. These data, however, suggest that the MSCs should be 
transplanted after IL-6 responses cease, in order not to disturb the 
MSCs functions or provoke the immune systems in vivo.
Aside from cytokines, baculovirus transduction stimulated 
transient, low level upregulation of HLA-I on the MSCs surface, 
but barely influenced the HLA-II expression (Figure 3). Again, 
such response contradicted the DCs response to baculovirus 
transduction, which led to a striking upregulation of a number 
of surface molecules, including HLA-I and HLA-II.21,35 The dis-
crepancy might arise from the fact that the undifferentiated MSCs 
only express moderate levels of HLA-I and low levels of HLA-II, 
hence baculovirus transduction probably was insufficient to trig-
ger dramatic changes in the surface expression of HLA. Since 
HLA-I and HLA-II play pivotal roles in presenting endogenously 
synthesized and phagocytosed peptides to CD8+ and CD4+ 
T cells, the negligible induction of HLA-II as well as transient, low 
level induction of HLA-I are desired with regard to minimizing 
the presentation of peptides derived from the baculovirus or the 
transgene to T cells. Additionally, baculovirus-transduced and 
mock-transduced MSCs inhibited similar degrees of PBMC pro-
liferation (Figure 4), attesting that baculovirus transduction does 
not impair the immunosuppressive property of MSCs.
Very importantly, after transplantation into allogeneic rats 
the mock-transduced rat MSCs were uniformly distributed and 
resided near the transplantation site without appreciable signs of 
cell clearance (Figure 5). The transduced MSCs were similarly 
tolerant in the recipient rats without signs of acute rejection, 
although the cells were transplanted at a time point when the 
responses  culminated (at 24 hpt when IL-6 and HLA-I reached 
the maximum). Although the transduced MSCs resulted in the 
recruitment of macrophages into the injection site at day 1 post-
transplantation, such inflammation response subsided at day 5 and 
virtually disappeared at day 10 (Figure 6a). Furthermore, CD8+ 
T cells were barely observed at the transplantation site throughout 
the experiment (Figure 6b), indicating the absence of  adaptive 
immune response. Besides the local response, transplantation 
of the transduced MSCs did not provoke significant systemic 
induction of monocytes and CD8+ T cells (Figure 7). These data 
 collectively attest that transplanting baculovirus-transduced MSCs 
into allogeneic immunocompetent animals only elicits inflamma-
tion responses that are mild, transient, and local, but provokes no 
rejection responses. These mild responses could be attributed to 
the low levels of cytokine induction and negligible perturbation of 
immunological characteristics of MSCs.
To our best knowledge, this is the first study exploring the 
responses of MSCs to virus transduction, although genetic modi-
fication of MSCs using various virus vectors has been reported.36–41 
Our data unveils that baculovirus transduction of undifferentiated 
MSCs elicits distinct cytokine expression profile as compared with 
differentiated immune cells, and triggers transient upregulation of 
HLA-I expression, but does not compromise other immunologi-
cal properties of MSCs. Furthermore, the baculovirus- transduced 
MSCs retained the immunoprivileged properties as they can 
evade immune recognition in allogeneic rats. These findings con-
firm the safety of transplanting baculovirus-transduced MSCs 
into  immunocompetent animals.
MAterIAls And MetHods
Preparation and culture of bone marrow–derived MSCs. Human bone 
marrow–derived MSCs were obtained from Cambrex (Walkersville, MD) 
and the subsequent MSCs selection, enrichment, and culture were per-
formed as described.11 Rat MSCs were obtained from the bone marrow 
of 6-week-old male LEW/SsNNarl rats. The femoral and tibial midshaft 
bone marrow was flushed into α-minimum essential medium (α-MEM) 
containing 20% fetal bovine serum (FBS; GIBCO, Grand Island, NY), 100 
U/ml penicillin, 100 mg/ml streptomycin, and 0.25 µg/ml amphotericine 
(Sigma, St Louis, MO). A single-cell suspension was obtained by sequen-
tially drawing the marrow into syringes through needles of decreasing size 
(gauge 18, 20, 22, respectively) and primary cultures of MSCs were seeded 
to 10-cm dishes (5 × 107 cells/dish). After 4 days of culture in a 37 °C, 5% 
CO2 incubator, the medium was replaced with fresh medium to remove 
nonadherent cells. MSCs were subcultured to passage 3 for transduction 
and transplantation.
Baculovirus preparation and transduction. A recombinant baculovirus 
that expressed no transgenes in mammalian cells was used throughout the 
study. The virus was amplified by infecting insect cells (Sf-9) cultured in 
TNM-FH medium containing 10% FBS, harvested by low speed centrifu-
gation (1,000g for 5 minutes) and stored at 4 °C until use. The virus titer 
was determined by end-point dilution method.42 Alternatively, the infected 
culture supernatant was ultracentrifuged (80,000g for 90 minutes) to yield 
the virus-free supernatant.
Human and rat MSCs were transduced as described14 with minor 
modifications. In brief, MSCs were seeded onto six-well plates (2 × 105 
cells/well) and cultured overnight. A certain volume of virus supernatant 
was mixed with phosphate-buffered saline (PBS) (pH 7.4) to adjust 
the final volume to 500 µl (per well). The transduction was initiated by 
directly adding the virus mixture to the cells and continued by gently 
shaking the six-well plates on a rocking plate for 4 hours at 25–27 °C. 
As controls, MSCs were incubated under the same conditions with the 
solution consisting of 400 µl PBS and 100 µl virus-free culture supernatant 
(supernatant) or TNM-FH medium (mock-transduction). After the 
incubation period, the cells were again washed with PBS and replenished 
with 2 ml α-MEM containing 20% FBS for culture at 37 °C.
Quantitative real-time reverse transcription PCR. Total mRNA was iso-
lated using RNeasy Mini Kit (Qiagen, Falencia, CA) and reverse tran-
scribed to cDNA for 60 minutes at 37 °C using the RevertAid H Minus 
First Strand cDNA Synthesis kit (Fermentas, Hanover, MD). The cDNA 
was mixed with SYBR Green PCR Master Mix (Applied Biosystems, 
Foster City, CA) and subjected to real-time PCR using the primer pairs 
summarized in Table 1. The real-time PCR was performed using ABI 
7300 (Applied Biosystems) under the following conditions: 2 minutes at 
50 °C, 10 minutes at 95 °C, and then 40 cycles of 15 seconds at 95 °C and 
table 1 the primer sequences used for quantitative real-time reverse 
transcription-Pcr
Gene Forward reverse
IL-1β TCCCCAGCCCTTTTGTTGA TTAGAACCAAATGT 
GGCCGTG
IL-6 GACAGCCACTCACCTCTTCA TTCACCAGGCAAG 
TCTCCTC
TNF-α CCCAGGCAGTCAGATCATCTT TCTCAGCTCCACGCCATT
IFN-α GGTGCTCAGCTGCAAGTCAA GCTACCCAGGCTGTGGGTT
IFN-γ ATGTATTGCTTTGCGTTGGACA TCAATAGCAACAAAAAG 
AAACGAGAT
gapdh CCACCCATGGCAAATTCC TGGGATTTCCATTGA 
TGACAA
IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
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1 minute at 60 °C. For each reaction, a no-template reaction was included 
as the negative control. The threshold cycle values of the target genes 
were normalized against that of the internal control gapdh. The data 
obtained at different time points were normalized against those of the 
mock-transduction control at 12 hpt.
ELISA. The spent media from the MSCs culture were collected at 24, 48, 
and 96 hpt and completely replaced with fresh media. The concentrations 
of IL-1β, IL-6, and IFN-α in the media were measured using Module set 
ELISA kits (Bender Medsystems, Vienna, Austria).
Flow cytometry for HLA expression. The transduced cells were trypsinized 
at 24, 48, and 144 hpt, washed and resuspended in PBS. Approximately 
2 × 105 cells were incubated at 4 °C for 20 minutes with fluorescein iso-
thiocyanate-conjugated monoclonal antibody (MAb) specific for HLA-I 
(antihuman HLA-ABC; eBioscience, San Diego, CA) or phycoerythrin-
conjugated MAb specific for HLA-II (antihuman HLA-DR; eBioscience), 
and then analyzed by a flow cytometer (FACSCalibur; BD Biosciences, San 
Diego, CA). The mock-transduced cells were treated similarly to serve as 
controls. The percentage of fluorescing cells and MFI of each sample were 
measured three times by counting 10,000 cells in each measurement.
Mixed lymphocyte culture. The transduced and mock-transduced MSCs 
were harvested at 24, 48, or 144 hpt, treated with mitomycin-C (40 µg/
ml; Sigma) for 30 minutes to stop MSCs proliferation and then seeded 
onto 96-well plates (2 × 104 cells/well). The PBMC were obtained by 
means of Histopaque-1077 (Sigma) gradient separation of peripheral 
blood from healthy donors. Purified PBMC were suspended in RPMI-
1640 medium (Sigma) containing 5 µg/ml phytohaemagglutanin-L 
(PHA-L; Sigma) and 10% FBS, and added to the wells containing MSCs 
at a ratio of 1:10 (MSCs: PBMC). After 48 hours of incubation, 20 µl of 
10 µmol/l BrdU (Merck, Darmstadt, Germany) was added to each well 
for 24 hours, and the proliferation of PBMC was measured using the 
BrdU cell  proliferation assay kit (Merck) as described.27 In parallel, the 
PBMC were cultured in the presence of PHA-L for 3 days and their pro-
liferation was defined as 100%.
Transplantation of baculovirus-transduced MSCs. Bone marrow –derived 
MSCs isolated from LEW/SsNNarl rats were transduced or mock-
 transduced and then cultured in α-MEM containing 10 µmol/l BrdU 
for prelabeling. At 24 hpt, the cells were trypsinized and resuspended in 
α-MEM (4 × 106 cells per 300 µl). To indentify the transplantation site 
after injection, 300 µl cell suspensions were mixed with 200 µl carbon black 
 dispersion solution (Faber-Castell, Newark, NJ). The cell suspensions were 
injected into LEW/SsNNarl rats in the lateral regions of quadriceps using 
1 ml syringes and 23 G needles.
Immunohistochemical staining. The rats were sacrificed at different times 
post-transplantation (n = 3 for each time point) in compliance with the 
Guide for the Care and Use of Laboratory Animals prepared by the Institute 
of Laboratory Animals Resources, National Science Council. The trans-
plantation site was identified by the carbon black. The tissue specimens 
were removed, fixed, and sectioned, and the sections were deparaffinized 
and rehydrated using xylene and a gradient of ethanol (100, 90, 70, 50, and 
0%, respectively). The sections were treated with Target Retrieval solution 
(Dako, Hamburg, Germany) for 10 minutes at 90 °C and then blocked with 
PBS containing 10% FBS for 30 minutes at room temperature. Depending 
on the target, the sections were incubated at 4 °C overnight with mouse 
anti-BrdU MAb (1:100 dilution; Abcam, Cambridge, UK), mouse anti-
macrophage MAb (1:100 dilution; Abcam), or mouse anti-CD8 MAb 
(1:100 dilution; GeneTex, San Antonio, TX). After washing, the sections 
were incubated with goat antimouse IgG conjugated with Alexa Fluor 488 
(Invitrogen, Carlsbad, CA) for 1 hour in the dark. Finally, the sections 
were mounted with the mounting medium containing 4′,6-diamidino-2-
phenylindole (DAPI; Vector Labs, Burlingame, CA). These were observed 
using a fluorescence microscope and photographed.
Quantification of systemic immune response. The rats were sacrificed at 1, 
5, and 10 days post-transplantation and the PBMC were collected from the 
hearts. In parallel, the PBMC were collected from healthy animals with-
out transplantation to serve as the control. The purified PBMC (5 × 105 
cells/ml) were incubated with mouse antimonocyte MAb (1:100 dilution; 
Abcam) or mouse anti-CD8 MAb for 20 minutes at 4 °C in the dark. After 
washing, the PBMC were incubated with goat antimouse IgG conjugated 
with Alexa Fluor 488 for 20 minutes at 4 °C in the dark. The percentage of 
fluorescing cells and MFI were measured three times by flow cytometry.
Statistical analysis. Statistical analyses for gene transcription, IL-6 
 secretion and PBMC proliferation were performed using independent 
samples t-tests. Statistical analyses for monocyte and CD8+ T cells in the 
blood were performed by analysis of variance in conjunction with post hoc 
analyses. The data are expressed as mean ± SD or mean values of three 
independent experiments. P < 0.05 was considered significant.
suPPleMentAry MAterIAl
Figure S1. Baculovirus transduction of MSCs stimulates the TLR3 
expression.
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